To describe patient and prescriber characteristics and factors associated with utilization of romosozumab in Denmark.MethodsThis registry‑based Danish retrospective cohort study comprised females aged ≥ 50 receiving osteoporosis medication from September 2020 − October 2023. Three cohorts were identified: those treated with romosozumab (cohort 1), those with osteoporosis‑related fracture within the last three years treated with other osteoporosis medications (cohort… Continue reading Treatment patterns of #romosozumab in postmenopausal women with severe #osteoporosis in Denmark: findings from the ROmosozumab in Scandinavia real-world Evidence Study (ROSES)